JAK2 and essential thrombocythemia: The phosphorylated and activated JAK2 can phosphorylate tyrosine in cytoplasmic domain of c-MPL and it provides a docking site for downstream signaling molecules .Studies from Western countries have shown that the approximate frequency of c-MPL gene mutations is 5-10% in PMF and ET patients [7-9].